NeoGenomics (NEO) Stock Forecast, Price & News

NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

Is NeoGenomics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics or view top-rated stocks.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for NeoGenomics.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings results on Wednesday, April, 27th. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. The medical research company had revenue of $117.17 million for the quarter, compared to analysts' expectations of $116.44 million. NeoGenomics had a negative net margin of 7.33% and a negative trailing twelve-month return on equity of 6.62%. NeoGenomics's revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.06) earnings per share.
View NeoGenomics' earnings history.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its first quarter 2022 earnings guidance on Monday, April, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of -$118 million, compared to the consensus revenue estimate of $119.16 million.

What price target have analysts set for NEO?

10 equities research analysts have issued 12-month price objectives for NeoGenomics' shares. Their forecasts range from $16.00 to $55.00. On average, they anticipate NeoGenomics' stock price to reach $24.64 in the next twelve months. This suggests a possible upside of 180.3% from the stock's current price.
View analysts' price targets for NeoGenomics or view top-rated stocks among Wall Street analysts.

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:

• Ms. Lynn A. Tetrault Esq., J.D., Exec. Chairman & Principal Exec. Officer (Age 59, Pay $97.67k)
• Ms. Halley E. Gilbert Esq., J.D., Chief Legal Officer & Corp. Sec. (Age 52, Pay $445.38k)
• Mr. George A. Cardoza, Pres & COO of Lab Operations (Age 60, Pay $800.5k) (LinkedIn Profile)
• Ms. Kathryn B. McKenzie, Chief Sustainability & Risk Officer (Age 38, Pay $793.48k) (LinkedIn Profile)
• Prof. Clive D. Morris M.B.A., M.D., Pres at Inivata (Age 51, Pay $940.31k)
• Mr. William Bishop Bonello, Chief Financial Officer (Age 57)
• Ms. Cynthia J. Dieter, Chief Accounting Officer (Age 47)
• Mr. John Mooney, Chief Technology Officer
• Dr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D., Exec. VP of R&D and Chief Scientific Officer
• Charlie Eidson, Director of Investor Relations and Corp. Devel.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NeoGenomics' key competitors?

Some companies that are related to NeoGenomics include Premier (PINC), The Ensign Group (ENSG), CRISPR Therapeutics (CRSP), Aspen Pharmacare (APNHY), Oak Street Health (OSH), ICU Medical (ICUI), Lantheus (LNTH), Quidel (QDEL), Novavax (NVAX), Amedisys (AMED), Abcam (ABCZY), iRhythm Technologies (IRTC), Hikma Pharmaceuticals (HIK), AMN Healthcare Services (AMN) and Ortho Clinical Diagnostics (OCDX).
View all of NEO's competitors.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.40%), Wellington Management Group LLP (8.07%), Brown Advisory Inc. (3.69%), State Street Corp (3.17%), Northern Trust Corp (1.21%) and Dimensional Fund Advisors LP (1.13%). Company insiders that own NeoGenomics stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics.

Which major investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Wellington Management Group LLP, Eagle Asset Management Inc., Verition Fund Management LLC, Granite Investment Partners LLC, Granahan Investment Management LLC, American Century Companies Inc., and Dimensional Fund Advisors LP. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, Robert J Shovlin, and William Bonello.
View insider buying and selling activity for NeoGenomics or view top insider-selling stocks.

Which major investors are buying NeoGenomics stock?

NEO stock was purchased by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Royce & Associates LP, Citigroup Inc., Renaissance Technologies LLC, Engineers Gate Manager LP, Emerald Advisers LLC, Samjo Capital LLC, and Cowen Prime Advisors LLC.
View insider buying and selling activity for NeoGenomics or or view top insider-buying stocks.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $8.79.

How much money does NeoGenomics make?

NeoGenomics has a market capitalization of $1.10 billion and generates $484.33 million in revenue each year. The medical research company earns $-8.35 million in net income (profit) each year or ($0.320010) on an earnings per share basis.

How many employees does NeoGenomics have?

NeoGenomics employs 2,000 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600, via email at [email protected], or via fax at 239-690-4237.